FOLFIRI, Bevacizumab 10 mg Not More Effective Than 5 mg for Colorectal Cancer

Share this content:
Bevacizumab 10mg/kg plus FOLFIRI as second-line treatment did not prolong progression-free survival compared with 5mg/kg in colorectal cancer.
Bevacizumab 10mg/kg plus FOLFIRI as second-line treatment did not prolong progression-free survival compared with 5mg/kg in colorectal cancer.

Bevacizumab 10mg/kg plus FOLFIRI (leucovorin, fluorouracil, irinotecan) as second-line treatment after first-line bevacizumab plus oxaliplatin-based therapy did not prolong progression-free survival compared with bevacizumab 5mg/kg plus FOLFIRI in patients with metastatic colorectal cancer (mCRC), a recent study published online first in the journal Annals of Oncology has shown.

For the phase III study, researchers enrolled 387 patients between September 2009 and January 2012 from 100 institutions in Japan and randomly assigned them to receive FOLFIRI plus bevacizumab 5mg/kg or 10mg/kg in 2-week cycles until disease progression.

Results showed that among the 369 evaluable patients for efficacy, the median progression-free survival was 6.1 months in the 5mg/kg group and 6.4 months in the 10mg/kg group (HR = 0.95; 95% CI: 0.75-1.21; = 0.676).

RELATED: Capecitabine Plus Bevacizumab Effective as Maintenance for Colorectal Cancer

Median time to treatment failure was 5.2 months in both groups (HR = 1.01; 95% CI: 0.81-1.25; P = 0.967). Data for overall survival is not yet mature.

In regard to safety, adverse event rates were similar in both groups

The findings suggest that if bevacizumab is continued after first-line therapy in patients with mCRC, a 5mg/kg-dose is appropriate for second-line therapy.

Reference

  1. Iwamoto S, Takahashi T, Tamagawa H, et al. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol. 2015. [Epub ahead of print]. doi: 10.1093/annonc/mdv197.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters